Drugs / A-CAR032
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07344311 | Jan 2026 → Jan 2027 expected | castration-resistant prostate carcinoma | Shanghai AbelZeta Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A-CAR032 | “A Phase I Trial of A-CAR032 in Participants With mCRPC” NCT07344311 ↗ |
| Modality | Cell therapy | “CAR T-Cell Injection” NCT07344311 ↗ |
| Route | Intravenous | “single infusion intravenously.” NCT07344311 ↗ |
| Target | STEAP2 | “STEAP2-targeted” NCT07344311 ↗ |